

East Lancashire Hospitals NHS Trust – NIHR performance in delivering research – 01.07.2015 to 30.09.2015

Research Ethics Committee Reference Number	Name of Trial	Target number of patients available	Target number of patients	Date Agreed to recruit target number of patients available	Date Agreed to recruit target number of patients	Trial Status	Target met within the agreed time	Comments
14/SC/0065	CANVAS-R: A randomised multicentre, double-blind,parallel, placebo-controlled study of the effects of Canagliflozin on renal endpoints in adult subjects with type 2 diabetes mellitus	Available	12	Available	30/06/2017	Closed - In Follow Up	Y	Sponsor closed screening on 20.03.2015 to avoid over enrolment into the study
13/LO/1438	User assessment of the NovaLife one-piece skin barrier	Available	4	Available	30/06/2014	Closed - Follow Up Complete	Y	
13/LO/0528	PIONEER: An Open-label, Randomised, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention	Available	1	Available	30/08/2015	Closed - Follow Up Complete	N	Sponsor confirmed that the recruitment period will be extended for our site and the agreed recruitment target date is now 30/08/2015. A patient was identified but not entered into the study due to the fact that the study was closed at this site by the sponsor on 2 June 2015 ahead of the agreed recruitment end date of August 2015
14/NW/1462	TM Reverse: Prospective Post Market Clinical Follow-Up Study of the Zimmer Trabecular Metal Reverse Shoulder System	Available	40	Available	30/06/2026	Open	N/A	
13/LO/1277	SPARTAN: A multi-centre, randomised, double blind, placebo-controlled, phase III of ARN-509 in men with non-metastatic (MO) castration-resistant prostate cancer	Available	3	Available	30/06/2016	Open	N/A	
14/SC/1161	Prospective single-arm, multi-centre, observational registry to further validate safety and efficacy of the ultimaster DES in real-world patients	Available	64	Available	30/11/2017	Open	N/A	

14/NE/1214	A randomised, open-label, multicentre, phase 2 trial comparing veliparib plus carboplatin and paclitaxel versus investigator's choice of standard chemotherapy in subjects receiving first cytotoxic chemotherapy for metastatic or advanced non-squamous non-small cell lung cancer (NSCLC) and who are current or former smokers	Available	7	Available	29/02/2016	Open	N/A	
13/NI/0123	MILES UK: Post marketing, multicentre, single arm, observational clinical registry to evaluate safety and efficacy of biomimetic sirolimus eluting stent system in all comers real world population with coronary artery stenosis in United Kingdom	Available	2	Available	31/05/2015	Open	Y	Sponsor confirmed that they would appreciate our support to enrol maximum number of subjects possible in the study until 31 May 2015. Sponsor has received REC approval for a minor amendment to extend enrolment to the study, although our target has not been altered and has already been met.
15/LO/0802	The effect of standard versus high energy, low volume oral nutritional supplements in children requiring nutritional support – a pilot study	Available	5	Available	30/09/2017	Open	N/A	
15/LO/0897	A phase III open-label randomised study of MPDL3280A (Anti PD-L1 antibody) in combination with bevacizumab vs sunitinib in patients with untreated advanced renal cell carcinoma	Available	6	Available	01/07/2017	Open	N/A	
14/NW/0218	GLYCEMIC CONTROL AND TREATMENT SATISFACTION USING FINESSE VERSUS PEN FOR INITIATING BOLUS INSULIN DOSING IN TYPE 2 DIABETES MELLITUS PATIENTS NOT ACHIEVING GLYCEMIC TARGETS ON BASAL INSULIN WITH/WITHOUT ANTI-HYPERGLYCEMIC AGENTS	Available	8	Available	31/12/2016	Open	N/A	
14/SC/1059	CREDENCE: A randomized, Double-blind, Event-driven Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy	Available	3	No Date Agreed With Sponsor		Open	N/A	
15/NW/0431	A phase 2, two-arm multi-centre, open-label study to determine the efficacy and the safety of two different dose regimens of a pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in subjects with metastatic or surgically unresectable urothelial cancer with FGFR genomic alterations	Available	3	Available	30/11/2017	Open	N/A	